

Special Issue

Novel Treatments and Technologies for Retinal Diseases

Message from the Guest Editor

Recent advances in the pathophysiologic understanding, imaging biomarkers, artificial intelligence and clinical trial design of retinal diseases combined with technological advancements in aptamer antagonists, non-viral/viral gene-therapy, RNA interference, high affinity antibodies, receptor traps, and nanoparticle glyco-mimetics have led to several FDA-approved therapies for formerly unmet medical needs. These FDA approvals combined with the prevalence of these retinal diseases have led to an increase in the research interest in retinal diseases. The purpose of this Special Issue is to provide a snapshot of all aspects of these advancements from basic science to the identification of pathogenic molecular targets, the development of novel classes of therapeutics, the development of clinically relevant pre-clinical models, the use of artificial intelligence to determine when and how we use these novel therapeutics, and the validation of new FDA-approved endpoints. We aim for a focused yet comprehensive Special Issue.

Guest Editor

Dr. Michael John Tolentino

1. Department of Ophthalmology, University of Central Florida College of Medicine, Orlando, FL 32827, USA
2. Department of Ophthalmology, Orlando College of Osteopathic Medicine, Orlando, FL 34787, USA
3. Aviceda Therapeutics, Cambridge, MA 02142, USA

Deadline for manuscript submissions

closed (31 May 2025)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/195356

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)